Freenome
Freenome is a biotech company founded in 2014 with the mission to detect cancer in its earliest, most treatable stages through advanced blood tests. They combine multiomics technology with artificial intelligence to achieve this. The company emphasizes a rigorous clinical program to drive discovery, development, and validation of their tests. Freenome fosters a culture of collaboration among its multi-disciplinary team, focused on innovation and patient impact. Their business model appears to involve developing and offering early cancer detection tests, potentially through partnerships with biopharma and research institutions.
Freenome
Freenome is a biotech company founded in 2014 with the mission to detect cancer in its earliest, most treatable stages through advanced blood tests. They combine multiomics technology with artificial intelligence to achieve this. The company emphasizes a rigorous clinical program to drive discovery, development, and validation of their tests. Freenome fosters a culture of collaboration among its multi-disciplinary team, focused on innovation and patient impact. Their business model appears to involve developing and offering early cancer detection tests, potentially through partnerships with biopharma and research institutions.
TL;DR
Focus: Multiomics blood-based early cancer detection tests
Headquarters: Brisbane / South San Francisco, CA
Lead program: SimpleScreen CRC (colorectal cancer); PREEMPT CRC pivotal study
Employees (approx.): 416
Total disclosed funding: USD 1,451,550,000
Company Overview
Problem Domain
Early cancer detection / population screening
Founded
2014
Industry
Biotechnology / Diagnostics
Funding Track Record
USD 5,500,000
Seed funding reported June 2016
USD 65,000,000
Series A reported March 2017
USD 160,000,000
Growth round to commercialize colorectal cancer blood test reported July 2019
USD 300,000,000
Series D reported December 2021
USD 254,000,000
Financing announced Feb 15, 2024 led by Roche
Investor Signal
“Roche as strategic investor; participation from Andreessen Horowitz, Perceptive Advisors, RA Capital Management, Bain Capital Life Sciences and other institutional investors”